To investigate if TA33.Combo enabled the generation of tumor-specific CD8+ T cells, we performed an IFNγ ELISPOT assay on CD8+ T cells purified from the spleen of either control untreated or TA33.Combo-treated mice. This evidence concerns the gene IFNG and neoplasm.